GlassScriptPhysician profile
Juni Shrestha
NPI 1114707130
$2,303.35
in general payments reported to CMS, 2019-2025
21 companies · $1,045 in 2025
The $1,045 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $23.57 · 2024: $1,235 · 2025: $1,045.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,303.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,303.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $339.62 | 2023-2025 | Repatha, Otezla, Krystexxa |
| Astrazeneca Pharmaceuticals LP | $329.58 | 2024-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $263.97 | 2024-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $209.25 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $204.35 | 2024-2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $159.28 | 2024-2025 | Jardiance |
| Sumitomo Pharma America, INC. | $146.23 | 2024-2025 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $111.53 | 2024-2025 | |
| Lilly USA, LLC | $86.12 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $77.33 | 2025 | Shingrix, Penmenvy, Bexsero |
| Aimmune Therapeutics, INC. | $72.66 | 2024-2025 | Zenpep |
| Exact Sciences Corporation | $56.50 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Biogen, INC. | $50.07 | 2025 | Skyclarys |
| Ironwood Pharmaceuticals, INC | $44.68 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $28.90 | 2024-2025 | Zoryve |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $26.09 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.01 | 2024 | Trulance, Xifaxan |
| Dexcom, INC. | $21.97 | 2024 | Dexcom G6 Transmitter |
| Cipher Pharmaceuticals US LLC | $21.24 | 2025 | Natroba, Spinosad |
| Cranial Technologies, INC | $18.80 | 2024 | Doc Band |
| Merck Sharp & Dohme LLC | $13.17 | 2024 | Gardasil, Vaxelis, Gardasil 9 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Juni Shrestha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.